Prezista generics — when can they launch?
Prezista (DARUNAVIR) · Janssen Prods · 14 active US patents · 0 expired
Where Prezista sits in the generic timeline
Imminent generic cliff: earliest active US patent for Prezista expires in 2026 (~1 year from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Composition of Matter — 7 patents
- Other — 7 patents
Sample patent estate
Showing 6 of 14 active US patents. View full estate on the Prezista drug page →
-
This patent protects new forms of a HIV protease inhibitor and processes for producing them.USPTO title: Pseudopolymorphic forms of a HIV protease inhibitor
-
This patent protects new forms of a HIV protease inhibitor and processes for producing them.USPTO title: Pseudopolymorphic forms of a HIV protease inhibitor
-
This patent protects new forms of a HIV protease inhibitor and processes for producing them.USPTO title: Pseudopolymorphic forms of a HIV protease inhibitor
-
This patent protects new forms of a HIV protease inhibitor and processes for producing them.USPTO title: Pseudopolymorphic forms of a HIV protease inhibitor
-
This patent protects new forms of a HIV protease inhibitor and processes for producing them.USPTO title: Pseudopolymorphic forms of a HIV protease inhibitor
-
This patent protects new forms of a HIV protease inhibitor and processes for producing them.USPTO title: Pseudopolymorphic forms of a HIV protease inhibitor
Sources
- FDA Orange Book — patents listed against Prezista (NDA filed 2006)
- Prezista drug profile — full patent estate, indications, clinical trials, pricing
- Janssen Prods patent portfolio
- Patent cliff 2026 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Prezista — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →